The immunologic response to severe acute respiratory syndrome coronavirus 2
- PMID: 34871157
- DOI: 10.2500/aap.2021.42.210077
The immunologic response to severe acute respiratory syndrome coronavirus 2
Abstract
Background: The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated the worst global pandemic in a century, which has caused millions of infections and deaths as well as massive economic repercussions. Objective: As with any pathogenic virus, it is crucial to understand its unique interactions with the human immune system so that pharmaceutical and prophylactic interventions can be deployed to effectively control the pandemic. Methods: A literature search by using PubMed was conducted in 2020 with variants of the terms "COVID-19," "SARS-CoV-2," and "immunological response." English language articles that presented original data about the immunologic response to coronavirus disease 2019 (COVID-19) were selected for review. This article reviewed the current understanding of the innate and adaptive immune responses to SARS-CoV-2 infection, including their relationship to current therapeutic and diagnostic strategies. Results: SARS-CoV-2 uses several unique molecular techniques to evade detection by the innate immune system early in the course of infection, and upregulation of these innate immune pathways may possibly accelerate the time to recovery and prevent severe disease. Although the majority of cases results in the patients' recovery, a significant proportion of infections result in deaths prompted by the host's inflammatory overreaction to the infection, a response that can be attenuated with corticosteroids and potentially other immune modulators. Conclusion: Current work by the scientific community to further understand how SARS-CoV-2 interacts with the human immune system will be invaluable to our response and preparedness for future coronavirus pandemics.
Similar articles
-
Immunopathogenesis and immunobiology of SARS-CoV-2.Infez Med. 2021 Jun 1;29(2):167-180. Infez Med. 2021. PMID: 34061781 Review.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
A review on the immune responses against novel emerging coronavirus (SARS-CoV-2).Immunol Res. 2021 Jun;69(3):213-224. doi: 10.1007/s12026-021-09198-0. Epub 2021 Apr 29. Immunol Res. 2021. PMID: 33928531 Free PMC article. Review.
-
Potential pathogenesis of severe acute respiratory syndrome coronavirus 2.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):591-597. doi: 10.11817/j.issn.1672-7347.2020.200299. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 32879112 Review. Chinese, English.
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
Cited by
-
Eosinophilic esophagitis: from discovery to effective treatment.Allergy Asthma Proc. 2022 May 1;43(3):175-177. doi: 10.2500/aap.2022.43.220025. Allergy Asthma Proc. 2022. PMID: 35524360 Free PMC article. No abstract available.
-
The complexities of allergic diseases continue to challenge the allergist-immunologist.Allergy Asthma Proc. 2023 Mar 1;44(2):87-89. doi: 10.2500/aap.2023.44.230002. Allergy Asthma Proc. 2023. PMID: 36872449 Free PMC article. No abstract available.
-
Asthma biomarkers and COVID-19 continue to dominate current medical issues.Allergy Asthma Proc. 2022 Sep 1;43(5):363-367. doi: 10.2500/aap.2022.43.220062. Allergy Asthma Proc. 2022. PMID: 36065102 Free PMC article. No abstract available.
-
SARS-CoV-2 infection and the human immune system: A continuing journey of discovery.Allergy Asthma Proc. 2021 Nov 1;42(6):447-449. doi: 10.2500/aap.2021.42.210092. Allergy Asthma Proc. 2021. PMID: 34871151 Free PMC article. No abstract available.
-
A confluence of advanced treatment options for atopic dermatitis, eosinophilic lung diseases and chronic urticaria brought about by the revolutionary discovery of biologics and Janus kinase inhibitors.Allergy Asthma Proc. 2022 Nov 1;43(6):471-473. doi: 10.2500/aap.2022.43.220081. Allergy Asthma Proc. 2022. PMID: 36335419 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous